Understanding how Candida glabrata becomes resistant to antifungal treatments
Official title: Elucidating mediators of genetic instability in Candida glabrata
Funded at Hackensack University Medical Center · NIH-10738279 · Data updated 2026-11-12
This study is looking at how the fungus Candida glabrata becomes resistant to antifungal treatments, which could help improve care for patients dealing with infections caused by this fungus.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Hackensack University Medical Center NIH-funded |
| Lab location | 1 site (Hackensack, United States) |
| Project start | November 9, 2022 |
| Project end | October 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $233,303 |
| NIH project number | 5R21AI168729-02 |
| Project ID | NIH-10738279 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation or benefit from this research include patients with recurrent or difficult-to-treat Candida glabrata infections.
✕Less likely to help
Patients with infections caused by other types of fungi or those who do not have Candida glabrata infections may not receive any benefit from this research.
What this research studies
This research investigates the genetic mechanisms that allow the fungus Candida glabrata to develop resistance to antifungal medications, particularly azoles and echinocandins. By examining how DNA damage and repair processes contribute to genetic instability in this pathogen, the study aims to identify specific genetic variants that lead to drug resistance. The research involves laboratory experiments that simulate the interactions between C. glabrata and host immune cells, providing insights into how the fungus adapts and evolves in response to treatment. Patients with infections caused by this fungus may benefit from the findings, which could lead to more effective antifungal therapies.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients suffering from drug-resistant Candida glabrata infections.
How similar studies have gone: Previous research has shown that understanding genetic mechanisms of drug resistance in pathogens can lead to significant advancements in treatment strategies, suggesting that this approach has potential for success.
Where this research is happening
-
Hackensack University Medical Center
Hackensack, United States Active
Researchers
- Principal investigator: Shor, Erika — Hackensack University Medical Center
- Study coordinator: Shor, Erika
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.